| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Dimitrios Schizas, Aikaterini Mastoraki, Leon Naar, Eleftherios Spartalis, Diamantis I Tsilimigras, Georgia Sofia Karachaliou, George Bagias and Dimitrios Moris |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Dimitrios Moris, MD, MSc, PhD, Academic Fellow, Academic Research, Doctor, Research Fellow, Surgeon, Department of Surgery, Duke University Medical Center, Duke University,, 2301 Erwin Rd, Durham, NC 27710, United States. dimitrios.moris@duke.edu |
| Key Words |
Esophageal cancer; Histone deacatylases; Inhibitors; Drugs |
| Core Tip |
Esophageal cancer (EC) remains one of the most lethal malignancies, mainly due to its aggressive nature. In an effort to overcome chemotherapy resistance, it was discovered that histone acetylation/deacetylation equilibrium is altered in carcinogenesis, leading to changes in chromatin structure and altering expression of genes important in the cell cycle, differentiation and apoptosis. Therefore, histone acetylation was addressed as a potential novel chemotherapy drug target. Based on the literature, histone deacetylases (HDACs) have been associated with EC, with surveys elucidating that increased expression of certain HDACs correlates with advanced TNM stages, tumor grade, metastatic potential and decreased 5-year overall and disease-free survival. |
| Publish Date |
2018-11-07 02:30 |
| Citation |
Schizas D, Mastoraki A, Naar L, Spartalis E, Tsilimigras DI, Karachaliou GS, Bagias G, Moris D. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment. World J Gastroenterol 2018; 24(41): 4635-4642 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i41/4635.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i41.4635 |
